Trials / Completed
CompletedNCT01675791
A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet
A Dose-response Evaluation of ALK Tree AIT
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 637 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of this trial is to evaluate the dose-response relationship for the ALK tree AIT administered once daily in order to define a dose-range that would be suitable for at-home administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALK tree AIT 0.5 DU | |
| BIOLOGICAL | ALK tree AIT 1 DU | |
| BIOLOGICAL | ALK tree AIT 2 DU | |
| BIOLOGICAL | ALK tree AIT 4 DU | |
| BIOLOGICAL | ALK tree AIT 7 DU | |
| BIOLOGICAL | ALK tree AIT 12 DU | |
| BIOLOGICAL | ALK tree AIT Placebo |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-07-01
- Completion
- 2013-09-01
- First posted
- 2012-08-30
- Last updated
- 2014-01-22
Locations
2 sites across 2 countries: Finland, Netherlands
Source: ClinicalTrials.gov record NCT01675791. Inclusion in this directory is not an endorsement.